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Abstract
Antidepressants are frequently prescribed as co-analgesics in chronic pain. While their effi-
cacy is well documented for neuropathic pain, the evidence is less clear in musculoskeletal
pain conditions. The present study therefore evaluated the effect of the tricyclic antidepres-
sant imipramine on chronic low-back pain in a randomized, double-blinded placebo-con-
trolled design. To explore the mechanisms of action and the influence of drug metabolism,
multimodal quantitative sensory tests (QST) and genotyping for cytochrome P450 2D6
(CYP2D6) were additionally performed. A single oral dose of imipramine 75 mg was com-
pared to active placebo (tolterodine 1 mg) in 50 patients (32 females) with chronic non-spe-
cific low-back pain. Intensity of low-back pain was assessed on a 0–10 numeric rating scale
at baseline and every 30 minutes after drug intake. Multimodal QST were performed at
baseline and in hourly intervals for 2 hours. Pharmacogenetic influences of cytochrome
P450 were addressed by CYP2D6 genotyping. No significant analgesic effect was detected
neither on low-back pain nor on any of the sensory tests in the overall analyses. However,
evidence for an interaction of the imipramine effect and CYP2D6 genotype was found for
electrical and for pressure pain detection thresholds. Intermediate but not extensive meta-
bolizers had a 1.20 times greater electrical pain threshold (95%-CI 1.10 to 1.31) and a 1.10
times greater pressure pain threshold (95%-CI 1.01 to 1.21) 60 minutes after imipramine
than after placebo (p<0.001 and p = 0.034, respectively). The present study failed to demon-
strate an immediate analgesic effect of imipramine on low-back pain. Anti-nociceptive
effects as assessed by quantitative sensory tests may depend on CYP2D6 genotype, indi-
cating that metabolizer status should be accounted for when future studies with tricyclic anti-
depressants are undertaken.
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Introduction
Tricyclic antidepressants (TCAs) are frequently used in chronic pain therapy. Albeit most
effective in neuropathic pain [1,2], they are as well prescribed in many other painful condi-
tions, including fibromyalgia, headaches or chronic low-back pain. There are several reasons
for using TCAs in chronic low-back pain: they favorably influence concomitant mood disor-
ders, may improve sleep quality and exert an analgesic effect. The rationale for an analgesic
effect is the modulating action at serotonergic and noradrenergic pathways involved in noci-
ceptive transmission and endogenous pain modulation [3].
Some clinical studies have reported beneficial effects of TCAs in chronic low-back pain
[4,6], assessed by outcomes such as pain intensity or functional improvement after trial periods
of several weeks. These findings, however, might as well be related to the effects of TCAs on
sleep quality or mood, and therefore do not provide sufficient mechanistic information about
the action of these drugs. On the other hand, most of the mechanistic knowledge about the
anti-nociceptive properties of TCAs is derived from studies in animals or human volunteers
rather than pain patients. Here, it has indeed been shown that TCAs exert acute anti-nocicep-
tive effects [7–11] as assessed by quantitative sensory tests (QST), already after a single TCA
dose. With regard to acute pain, there is currently hardly any evidence for the use of antide-
pressants [12].
Pain practitioners are thus faced with two questions: does clinical improvement really sug-
gest a genuine analgesic effect of a TCA, and does anti-nociception assessed by QST also imply
a clinically meaningful treatment outcome?
An answer to this question might be provided by combining both the mechanistic and the
clinical approach in the same study. Unfortunately, studies comparing the analgesic effect of
TCAs in chronic pain with anti-nociceptive effects using QST are sparse. The present study
was part of a larger project investigating the prediction of the effect of different drugs on
chronic low-back pain [13] (S1 Appendix). Here, we report the results of a randomized, dou-
ble-blinded and placebo-controlled sub-study which investigated the effect of a single oral
dose of the TCA imipramine on both low-back and experimental pain in humans. Effects on
low-back pain and experimental pain (QST) were analyzed separately for genetic polymor-
phisms of cytochrome P450 2D6 (CYP2D6), the major metabolic pathway of imipramine.
Methods
Setting
The study took place at the University Department of Anesthesiology and Pain Therapy, Insel-
spital Bern, Switzerland between July 2010 and April 2014. It was approved by the local ethics
committee Kantonale Ethikkommission Bern (KEK 213/09) and registered at clinicaltrials.gov
(NCT01179828). All participants gave written informed consent prior to inclusion.
Patients
Consecutive patients aged between 18 and 80 years with chronic low-back pain of at least 3
months duration were recruited by advertisement in local newspapers and from our outpatient
pain clinic. Exclusion criteria were pain intensity at rest<3/10 on the numerical rating scale
(NRS) at the time of testing (whereby 0 = no pain and 10 = worst pain imaginable), suspected
radicular pain (as defined by leg pain associated with an MRI finding of a herniated disc or
foraminal stenosis), signs or suspicion of neurological dysfunction at the tested sites, pregnancy
(as assessed by pregnancy test), breast feeding, ongoing treatment with an antidepressant,
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opioid or anticonvulsant, intake of centrally active substances (including drug or alcohol
abuse), known allergy or pharmacological contraindications to imipramine or tolterodine
(active placebo), multi-site or widespread pain, systemic inflammatory or rheumatological dis-
ease, and major depression (Beck Depression Inventory short form score>9). Analgesic medi-
cation had to be stopped one week before the first experiment. Only acetaminophen or
ibuprofen were allowed as rescue medication until 24 hours before the experiments. Patients
unable to stop their analgesic regimen were not recruited.
Study medication
Previous studies in healthy volunteers used single oral imipramine doses of 100 mg [10,11]
with no serious adverse effects. Nevertheless, given that the present patient population would
be older and maybe more prone to side-effects, a single oral dose of imipramine 75 mg was
chosen. The anti-cholinergic compound tolterodine 1 mg was used as active placebo in a
cross-over fashion. Tolterodine is prescribed for hyperactive bladder disorders. It is a specific
antagonist at muscarinic M2- and M3-receptors and should be devoid of any analgesic effects,
but mimics some of the sedative side effects such as blurred vision, drowsiness and sleepiness.
This allowed for better blinding of patients and investigators than an ineffective placebo. A
minimal wash-out period of one week between sessions was ensured. The drugs were adminis-
tered as identical-looking red gelatin capsules in random order and in a fasting state. Blinding
and randomization were provided by the hospital pharmacy as described in detail in the study
protocol [13] (S1 Appendix).
Intensity of low-back pain
Intensity of low-back pain was assessed on a 0–10 NRS at baseline and in intervals of 30 min-
utes up to 2 hours after drug intake, both in the supine position and after 10 minutes of sitting.
The patients’ global impression of change scale (PGIC) was assessed on a 7 point scale ranging
from “1 = very much improved” over “4 = no change” to “7 = very much worse”, in intervals
of 30 minutes, starting 30 minutes after drug administration.
Quantitative sensory testing
Quantitative sensory testing was performed at baseline as well as one and two hours after drug
administration. All tests were performed at the more painful body side. In case of bilateral or
midline pain, the side was randomly selected. The detailed methodology is described elsewhere
[13] (S1 Appendix). In brief, pressure pain detection and tolerance thresholds (PPDT and
PPTT) were measured at the second toe using an electronic algometer (Somedic AB, Horby,
Sweden). Electrical single pain threshold (ESPT) and electrical repeated pain threshold (ERPT
with 5 stimuli at 2 Hz inducing temporal summation) were measured using a constant current
stimulator (Digitimer Ltd, Welwyn Garden City, UK) and two surface electrodes attached
below the lateral malleolus in the innervation area of the sural nerve. Heat pain detection and
tolerance threshold (HPDT and HPTT) as well as cold pain detection threshold (CPDT) were
measured at the ipsilateral leg at the L5-dermatome and the ipsilateral forearm at the C6-der-
matome using a Peltier thermode (TSA II, Medoc, Ramat Yishai, Israel). Conditioned pain
modulation (CPM) was assessed at baseline only using the cold pressor test of the contralateral
hand as conditioning stimulus. Electrical train of five stimulation at an intensity 1.2 times the
ERPT was rated by the subjects on a 0–10 NRS before and during the cold pressor test. The
percent decrease in ERPT rating during the cold pressor test was calculated as an indication of
CPM. Furthermore, the time until cold pressor pain reached 7/10 NRS was recorded. Hand
immersion in ice water was repeated after 1 and 2 hours and the time to NRS 7 was noted. For
Imipramine in low-back and experimental pain
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all tests, triplicate measurements were recorded. A complete series of training measurements
was performed before baseline assessments, in order to familiarize patients with the
procedure.
Descriptive variables and side effects of medication
The following descriptive variables were assessed on a questionnaire before the first study ses-
sion: age, sex, body mass index (BMI), pain duration in years, history of surgery due to the
painful condition, average pain intensity during the last 24 hours on a 0–10 NRS, pain-related
life interference from the multidimensional pain inventory (MPI), catastrophizing scale and
Beck Depression Inventory (BDI). Patients rated the intensity of nausea, dizziness and seda-
tion every 30 minutes after drug intake on a 0–10 NRS.
Genotyping
Genomic variants of cytochrome CYP2D6 were assessed by real time polymerase chain reaction
(PCR) and identification of specific variants by means of melting curve analysis. The following
alleles were examined: CYP2D6 3, 4, 5, 6, 8, 10 and 41 as well as gene multiplication.
Alleles with none of these variants were categorized as “wild-type” (wt, 1). Translation of the
genotypes into a qualitative measure of phenotype was made according to Gaedigk’s system of
“activity scores” [14]: alleles 3,4,5,6,7, and 8 were assigned a value of 0, alleles 10 and 41
a value of 0.5, the wild type (wt) allele a value of 1, and wtxN (representing multiplication of the
wt allele) a value of 2. The sum of the values assigned to each single allele resulted in a CYP2D6
activity score. Activity scores of 0 correspond to poor metabolizers (PM), scores of 0.5–1 to
intermediate metabolizers (IM); scores of 1.5–2 to extensive metabolizers (EM) and scores of 3
to ultra-rapid metabolizers (UM) with a duplication or multiplication of a functional allele.
Statistical analyses
Normal distribution of variables was checked by visual inspection using quantile plots. Contin-
uous and ordinal variables that were normally distributed (NRS) or normally distributed after
log-transformation (PPDT, PPTT, ESPT, and ERPT) were analyzed by linear mixed models,
with treatment group, time point and their interaction as covariates. The models were adjusted
for baseline values and treatment phase (verum first vs. placebo first) in order to account for a
possible learning effect. A carry-over effect was excluded by design (wash-out period between
the phases) and was not tested for. A random intercept was added for each subject (to account
for intra-subject correlation) and a random intercept and slope for each subject in each treat-
ment phase (to account for repeated measures). Correlations between subsequent measure-
ments were modeled with a first order autoregressive correlation structure. The treatment
effect was calculated over all time points (joint p-value) and at each time point based on mar-
ginal models. HPDT and HPTT which were truncated at 50.5˚C were analyzed by separate
mixed tobit regression models at each time point with treatment group and phase as covariates
and subject ID as panel variable. CPDT was dichotomized (reaching 0˚C) and analyzed by sep-
arate logistic GEEs at each time point with treatment group and phase as covariates and subject
ID as panel variable. Sample size considerations were based on a larger project and have
already been published [13] (S1 Appendix). For a subgroup analysis, CYP2D6 metabolizer
group and its interaction with treatment group were added to the models. All statistical analy-
ses were made using STATA (STATA Corp, College Station, Texas).
Imipramine in low-back and experimental pain
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Results
A total of 50 patients were enrolled (32 females), with a mean age of 54.4 years (SD 17.3 years)
and average pain duration of 11.2 years (SD 12.3). Descriptive variables are detailed in Table 1.
Study design and treatment allocation are shown in Fig 1. The CONSORT checklist can be
found in S2 Appendix.
Intensity of low-back pain
In terms of relief of low-back pain, imipramine was at no time point significantly different
from placebo, neither in the sitting nor in the supine position. Pain intensity in supine position
decreased from 4.2 to 2.6 after 2 hours in the imipramine arm and from 4.0 to 2.5 in the pla-
cebo arm (treatment effect 0.02 (-0.51 to 0.56), joint p = 0.950). The PGIC showed a corre-
sponding trend to minimal improvement in both arms (imipramine 3.6 (3.3 to 3.9), placebo
3.4 (3.1 to 3.7), treatment effect -0.2 (-0.6 to 0.2), joint p = 0.669).
Quantitative sensory testing
No effect could be observed on the QST measures, with the exception of a 1.05 times higher
PPTT in the imipramine session after 120 minutes (95%-CI 1.00 to 1.11), p = 0.038, Fig 2). The
remaining QST parameters (i.e. ESPT, ERPT, PPDT, PPTT, time of ice immersion and all
thermal pain tests) showed no significant change over time.
Genotyping–Effect of imipramine by CYP2D6 metabolizer status
During data analysis, QST results were plotted for each CYP2D6 metabolizer group. It became
apparent upon visual inspection that anti-nociceptive effects might depend on metabolizer sta-
tus. Subgroup analyses were therefore performed in order to check for interactions of imipra-
mine effect with metabolizer status. However, this subgroup analysis had to be restricted to
intermediate (n = 20) and extensive metabolizers (n = 26, thus roughly comparable in subsam-
ple size), because there were too few poor (n = 3) and ultra-rapid (n = 1) metabolizers. All
Table 1. Descriptive variables.
Number of patients 50
Age (years) 54.4 ± 17.3
Sex (female) 32 (64%)
BMI (kg/m2) 26.6 ± 4.6
Pain duration (years) 11.2 ± 12.3
Previous back surgery (yes) 10 (20%)
Average pain in 24h (0–10 NRS) 5.6 ± 1.8
Impairment of daily life (min: 0, max: 10) 2.4 ± 1.2
Catastrophizing score (min: 1, max: 6) 1.6 ± 1.2
Beck Depression Index (min: 0, max: 21) 2.3 ± 2.3
CYP2D6 PM 3 (6%)
CYP2D6 IM 20 (40%)
CYP2D6 EM 26 (52%)
CYP2D6 UM 1 (2%)
Continuous data are presented as means and standard deviations, ordinal data as numbers and percentages.
BMI = Body mass index, NRS = numeric rating scale, PM/IM/EM/UM = poor, intermediate, extensive and
ultrarapid metabolizers of CYP2D6.
https://doi.org/10.1371/journal.pone.0195776.t001
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patients were successfully genotyped. The frequency of each of the four metabolizer pheno-
types is displayed in Table 1. Mutant allele frequencies were 22.0% for 10, 19.0% for 4, 8.2%
for 41, 5.0% for 5. Mutant alleles for 3, 6 and 8 were not found at all. These numbers are
in line with Gaedigk’s in a Caucasian population [14].
Fig 1. Patient flow-chart. Flow-chart displaying study design and treatment allocation.
https://doi.org/10.1371/journal.pone.0195776.g001
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Again, relief of low back pain after medication was not different between imipramine and
placebo, but a significant effect on QST could be detected in intermediate metabolizers of
CYP2D6. This was most pronounced for ESPT: intermediate metabolizers had 1.20 (1.10 to
1.31) and 1.15 (1.04 to 1.26) times higher ESPT 60 and 120 minutes after imipramine com-
pared to placebo (p<0.001 and p = 0.006, respectively), whereas it remained almost unchanged
in extensive metabolizers. This interaction was highly significant (p = 0.007). A similar but
weaker trend for interaction could be observed in the ERPT measurements (interaction
p = 0.079).
After imipramine, intermediate metabolizers had a tendency towards higher PPDT after 60
and 120 minutes (1.10 (1.01 to 1.21), and 1.07 (0.97 to 1.17)), whereas extensive metabolizers
showed no such tendency (interaction p = 0.054). Intermediate metabolizers had 1.07 times
higher PPTT 120 minutes after imipramine compared to placebo (95%-CI 1.00 to 1.17,
p = 0.047), but a dependency on CYP2D6 metabolizer status was not found (interaction
p = 0.475). No significant differences between imipramine and placebo and hence no interac-
tion between genotypes were observed in the thermal QST. After imipramine, intermediate
metabolizers took longer until the cold pressor pain reached NRS 7/10 than after placebo
(mean ratios 1.20 (1.02 to 1.42), and 1.17 (0.98 to 1.40) at 60 minutes (p = 0.032) and a little
less so after 120 minutes (p = 0.08). An illustration of the interactions is displayed in Fig 3.
Table 2 displays the detailed results for electrical, mechanical and cold pressor tests. The results
of thermal QST are displayed in S1 Table.
Side effects
Nausea, dizziness and sedation occurred in both the imipramine and the tolterodine session.
Overall, side effects were rated very low, but nausea and dizziness occurred significantly
more after imipramine than after tolterodine. After 120 min, nausea was rated 0.3 (SD 0.9) in
the imipramine arm and 0.0 (0.1) in the tolterodine arm (p = 0.025). Dizziness after 120 min
was rated 0.6 (1.4) after imipramine and 0.1 (0.4) after tolterodine (p = 0.002). Overall, seda-
tion was the strongest side effect after 120 min with 1.4 (2.2) in the imipramine and 1.1 (1.8) in
the tolterodine arm. However, this was not significantly different (p = 0.452). Table 3 shows
the ratings of side effects for both drugs at every time point.
Discussion
This study failed to demonstrate an immediate analgesic effect of a single oral dose of imipra-
mine on non-specific low-back pain. Anti-nociceptive effects as assessed by QST were only
observed in intermediate metabolizers of CYP2D6, after additional subgroup analyses.
Imipramine and low-back pain
There are two possible reasons why no significant analgesic effect of imipramine on low-back
pain was detected in the present study. The first one is that a single oral dose may not be suffi-
cient. The literature commonly states that antidepressants start to be effective only after several
days [2,15]. This may be true for neuropathic pain conditions, where the benefit of antidepres-
sants is well documented. Nevertheless, there is no convincing explanation for this delayed
effect. Earlier studies have found TCAs to be effective in chronic low-back pain [4–6,16] after
Fig 2. Effect of imipramine on quantitative sensory tests. Imipramine effect on pressure pain detection (PPDT, a) and tolerance thresholds (PPTT, b), and
on electrical single pain detection threshold (ESPT, c) and electrical repeated pain threshold (ERPT, d) in all patients (n = 50), independent of genotype.
GMR = geometric mean ratio.
https://doi.org/10.1371/journal.pone.0195776.g002
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several weeks. However, none of these studies assessed whether an immediate analgesic effect
already occurred after the first dose.
A mechanistic proof of analgesia or anti-nociception requires a correlation in time between
drug intake and effect, ideally after single dose administration. Such a correlation can actually
be seen with the side effects of TCAs, like sedation or dry mouth which occur soon after drug
intake. When the analgesic effect of TCAs occurs with a delay, it may more likely be due to
mood stabilization and improved sleep quality, leading to overall improved clinical well-being,
rather than to analgesia.
The second explanation may be that imipramine is not effective in low-back pain at all. A
closer look at the literature reveals that only two studies have evaluated the effect of imipra-
mine on chronic low-back pain [4,17], and only a few more have investigated other tricyclic
compounds [5,6,16]. The results are remarkably controversial. Jenkins et al. report no signifi-
cant improvement after imipramine compared to placebo [17], whereas Alcoff et al. conclude
that imipramine was potentially useful [4]. Several systematic reviews on tricyclic antidepres-
sants for chronic low-back pain come to different conclusions [18–21], depending on which
original articles they include. The most recent study [22] used amitriptyline and concluded
that it was superior to pregabalin after 14 weeks of treatment. This was, however, an open-
Fig 3. Interaction of drug effect and genotype. Effect of imipramine (filled symbols) vs. placebo (open symbols) on electrical pain detection threshold with a single
(ESPT) or repeated stimulus (ERPT), on pressure pain detection (PPDT) and tolerance thresholds (PPTT) for intermediate (squares) and extensive (circles) CYP2D6
metabolizers. The interaction between imipramine effect and CYP2D6 genotype is suggested by the diverging lines within the first 60 minutes in intermediate
metabolizers (squares), whereas no such divergence is seen in extensive metabolizers (circles).
https://doi.org/10.1371/journal.pone.0195776.g003
Table 2. Quantitative sensory tests in intermediate and extensive metabolizers.
Time 2D6 subtype Marginal mean ratio (95% CI) p value p value for interaction
ESPT 60 intermediate metabolizer 1.20 (1.10 to 1.31) 0.000 0.007
extensive metabolizer 1.03 (0.96 to 1.11) 0.403
120 intermediate metabolizer 1.15 (1.04 to 1.26) 0.006
extensive metabolizer 0.99 (0.90 to 1.07) 0.736
ERPT 60 intermediate metabolizer 1.08 (0.98 to 1.18) 0.111 0.079
extensive metabolizer 0.97 (0.89 to 1.05) 0.451
120 intermediate metabolizer 1.05 (0.96 to 1.16) 0.284
extensive metabolizer 0.95 (0.87 to 1.03) 0.223
PPDT 60 intermediate metabolizer 1.10 (1.01 to 1.21) 0.034 0.054
extensive metabolizer 0.99 (0.91 to 1.07) 0.722
120 intermediate metabolizer 1.07 (0.97 to 1.17) 0.169
extensive metabolizer 0.96 (0.88 to 1.04) 0.278
PPTT 60 intermediate metabolizer 1.01 (0.94 to 1.08) 0.767 0.475
extensive metabolizer 0.98 (0.92 to 1.04) 0.506
120 intermediate metabolizer 1.07 (1.00 to 1.15) 0.047
extensive metabolizer 1.04 (0.98 to 1.11) 0.210
Iwsec 60 intermediate metabolizer 1.20 (1.02 to 1.42) 0.032 0.231
extensive metabolizer 1.05 (0.91 to 1.21) 0.483
120 intermediate metabolizer 1.17 (0.98 to 1.40) 0.080
extensive metabolizer 1.03 (0.88 to 1.20) 0.722
Effect of imipramine vs. placebo on pain detection threshold with a single (ESPT) or repeated electrical stimulus (ERPT), and on pressure pain detection (PPDT) and
tolerance thresholds (PPTT), and the time until cold pain reaches 7 on NRS (Iwsec) for different CYP 2D6 genotypes (intermediate vs. extensive metabolizers). The
effect is estimated on the log scale and presented as a mean ratio. A significant interaction would indicate that the effect differs between genotypes.
https://doi.org/10.1371/journal.pone.0195776.t002
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label trial without placebo control. The latest Cochrane review from 2008 does not at all sup-
port the use of antidepressants in chronic low-back pain [21]. The results of the present study
do not imply that imipramine is ineffective in low-back pain, but suggest mechanisms of
action other than analgesia.
Imipramine and QST
The anti-nociceptive properties of imipramine have been well documented in several previous
studies. In animals, these effects are nearly immediate, and can be measured 5 minutes after
intravenous [23] or 1 hour after intraperitoneal administration [24,25]. In human volunteers,
anti-nociceptive effects significantly superior to placebo were detected 90 minutes after oral
administration [7]. The present study, however, showed no effect in the primary analyses at
that time or later.
There are several possible explanations for this discrepancy. Firstly, two hours observation
time may have been insufficient. But given that peak plasma concentrations of imipramine are
reached between 2 and 3 hours [26], one would at least expect a trend in the last QST measure-
ments after 2 hours. Another explanation might be the choice of QST modalities. The study of
Poulsen et al. [11] showed a significant effect of imipramine on pain tolerance thresholds, but
none on pain detection thresholds. This could subsequently be replicated by Enggaard et al.
[10]. With the exception of PPTT (for which, notably, an anti-nociceptive trend was observed),
the stimuli in the present work were not exceedingly intense and therefore, relevant effects
may have been missed. More intense pain paradigms such as electrical pain tolerance, ischemic
pain or a capsaicin model may be considered for future studies. A study by Wallace et al. [27]
found that skin touch as well as warm and cold sensation thresholds remained unchanged by
desipramine. They concluded that desipramine had no effect on acute nociception, but they
had not tested any pain tolerance thresholds. The most intriguing explanation, however, why
imipramine had no effect in the in the present study may be that the onset of anti-nociception
depends on the speed of drug metabolism. Imipramine is partly transformed to its active
Table 3. Occurrence of nausea, dizziness and sedation after drug intake.
Imipramine Tolterodine p-value
Nausea
30 min 0.2 (0.8) 0.0 (0.2) 0.146
60 min 0.0 (0.1) 0.0 (0.1) n/a
90 min 0.1 (0.5) 0.0 (0.2) 0.371
120 min 0.3 (0.9) 0.0 (0.1) 0.025
Dizziness
30 min 0.5 (1.3) 0.1 (0.6) 0.024
60 min 0.4 (1.2) 0.1 (0.5) 0.119
90 min 0.5 (1.2) 0.1 (0.4) 0.021
120 min 0.6 (1.4) 0.1 (0.4) 0.002
Sedation
30 min 1.2 (1.9) 1.3 (2.1) 0.755
60 min 1.3 (2.1) 1.5 (2.3) 0.460
90 min 1.3 (2.1) 1.3 (2.1) 0.963
120 min 1.4 (2.2) 1.1 (1.8) 0.452
Intensity of side effects nausea, dizziness and sedation, rated on a numeric rating scale between 0 (no side effect at all)
and 10 (maximally imaginable side effect). Values are displayed as means (standard deviation).
https://doi.org/10.1371/journal.pone.0195776.t003
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metabolite desipramine by N-demethylation via CYP2C19. Both imipramine and desipramine
are hydroxylated to 2-Hydroxy-imipramine and 2-Hydroxy-desipramine by CYP2D6, which
are the rate-limiting steps [28]. These occur somewhat faster in extensive than in intermediate
metabolizers. During the short observation period of two hours, when enteral absorption may
still be in progress, plasma levels rise more slowly in extensive metabolizers because more of
the active compounds are hydroxylated by CYP2D6. This may explain why only intermediate
metabolizers showed anti-hyperalgesic effects at that time. The overall analysis showed no net
effect on QST, because the effect in intermediate metabolizers was counterbalanced by a lack
of effect in extensive metabolizers. Anti-hyperalgesic effects may therefore become evident
only when genotypes are analyzed separately.
To our knowledge, none of the previous studies took different CYP2D6 genotypes into
account. Rather, Poulsen et al. [11] had explicitly enrolled only extensive metabolizers of imip-
ramine. Trends to anti-nociceptive effects in these extensive metabolizers were noted 3–6
hours after drug intake. In the present study, extensive metabolizers might as well have shown
such effects, had the observation time been longer. Intermediate metabolizers, on the other
hand, started to show anti-nociceptive effects already after 2 hours. One might hypothesize
that both intermediate and extensive metabolizers of imipramine experience anti-nociceptive
effects, but that they occur sooner in intermediate and only later in extensive metabolizers.
Strengths and limitations
Most of the previously published work was performed on healthy volunteers using sample
sizes between 10 and 20 individuals [7–11,27]. In contrast, the present study enrolled chronic
pain patients, and the results are therefore more clinically relevant. Our sample is by far the
largest one that examines imipramine and QST. Patients presented with homogeneous clinical
findings, and were properly randomized and blinded. Given the possible delayed onset of
action of TCAs, administration of a single oral dose may be debatable. However, the study
aimed at detecting an analgesic effect. If this had been clinically relevant, it should have been
detectable even after single dose administration. The relatively short observation time of 2
hours is a limitation of the study, as is the lack of measurements of imipramine plasma concen-
trations. It is known that plasma concentrations depend on metabolizer status [29], but not
whether analgesic or anti-hyperalgesic effects correlate with plasma concentrations. Demon-
strations of lacking drug effect despite adequate plasma concentrations would have supported
our conclusions. The interaction analysis was not defined in the study protocol and has to be
considered a post-hoc analysis with exploratory character. Multiple statistical testing has been
performed and has to be taken into consideration when interpreting the reported p-values,
since no correction for multiple comparisons was attempted.
Conclusions
The present study revealed no analgesic effect after a single oral dose of imipramine within 2
hours in chronic low-back pain patients. It does not necessarily challenge the clinical practice
of prescribing TCAs in chronic low back pain. It suggests, however, that their effects may not
be the result of an analgesic process in the classical sense. Other actions, such as mood and
sleep modulation, may be more important than a direct analgesic effect. Furthermore, the
study suggests that imipramine may have anti-nociceptive properties that depend on CYP2D6
metabolizer status and become evident only in experimental but pain tests. This finding has
not been reported before and should be taken into account when planning future studies using
tricyclic antidepressants.
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